This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Modybody Program (ASLAN/NTU)

ASLAN Pharmaceuticals Pte Ltd

Drug Names(s): Modybody Program (ASLAN/NTU)

Description: ASLAN Pharmaceuticals and Nanyang Technological University (NTU) are developing Modybodies, a novel type of stabilised heavy chain monoclonal antibody (mAb) fragments.

Deal Structure: ASLAN and NTU Singapore
In October 2016, ASLAN Pharmaceuticals entered into a licensing and research collaboration agreement with Nanyang Technological University, Singapore (NTU Singapore) for the development of Modybodies, a novel type of stabilised heavy chain monoclonal antibody (mAb) fragments.

ASLAN will collaborate with NTU on the development of Modybodies against three targets of ASLANs choice and has an exclusive option, under pre-negotiated terms, to obtain global rights to develop and commercialise Modybodies. ASLAN expects the first Modybody from the collaboration to enter clinical development in 2018. The technology originated from a laboratory at NTUs School of Biological Sciences. Commercial terms of the agreement were not disclosed.


Modybody Program (ASLAN/NTU) News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug